RXi Pharmaceuticals

Marlborough-based RXi Pharmaceuticals is forging ahead into new territory to create new cancer treatments using its RNAi technology.

Marlborough drugmaker RXi Pharmaceuticals has begun working with a California biotherapeutic firm to evaluate potential collaborations to create a new cancer treatment.

Marlborough drugmaker RXi Pharmaceuticals has been granted a U.S. patent for its method to treat or prevent fibrotic disorders, and hopes to market that intellectual property as it continues to focus on cancer research.

More than 80 applicants have applied to the Marlborough Regional Chamber of Commerce board of directors to fill the vacant CEO position.

The longtime head of the Marlborough Regional Chamber of Commerce is retiring at the end of August, the chamber announced this month.

Marlborough startup drugmaker RXi Pharmaceuticals has agreed to terms with several entities for a $4.9 million investment intended to help fund preclinical and clinical work.

Marlborough-based biotech RXi Pharmaceuticals ended 2017 with $3.6 million in cash, about a third of what if had at the end of 2016, according to a financial statement released by the company Monday.

The Marlborough company is bringing Nobel Prize-winner Craig Mello's work into a burgeoning field of cancer research.

Marlborough drug maker RXi Pharmaceuticals has regained compliance with Nasdaq by having 10 straight days with a closing bid price of the company's stock at $1 per share or higher.

Marlborough drugmaker RXi Pharmaceuticals is shifting its business strategy to focus on the development of the most potentially lucrative of its three treatment areas.